Patients taking Kerendia saw significant reduction in cardiovascular death and hospitalization and urgent visits for heart ...

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

Researchers at the German Center for Cardiovascular Research (DZHK) have identified a key molecule involved in a form of ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

Medically reviewed by Christopher Lee, MDSystolic congestive heart failure, or systolic heart failure, is a type of heart ...

Heart failure, a condition where the heart struggles to pump blood efficiently to meet the body's needs, comes in various forms and one of them, heart failure with preserved ejection fraction ...

Heart failure normal ejection fraction (HFNEF) is growing at an alarming rate and has a complex pathophysiology. The mortality and morbidity of HFNEF is comparable to heart failure with reduced ...

The era of predictive modeling enhanced with machine learning and artificial intelligence (AI) to aid clinical ...

Part 3: Heart Failure With Reduced Ejection Fraction: Diagnosis and Evaluation. Part 4: Case Study: Lightheadedness, Fatigue in Man With Hypertension. Up next: Medical Management ...

Lungs Heart The phase 3 EMPEROR-Preserved trial assessed empagliflozin in 5988 adults with heart failure with preserved ejection fraction, with and without diabetes. Full results from the phase 3 ...